Tanzania: Tanzania Medicines and Medical Devices Authority Bans Heartburn Medications Over Cancer Risk
[Citizen] Dar es Salaam -All patients taking heartburn drugs with the active ingredient ranitidine must stop their course of treatment and report to a nearby health facility after authorities raised concern about the safety of the drugs. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 21, 2019 Category: African Health Source Type: news
Precision Dose Inc. Issues Voluntary Nationwide Recall of Ranitidine Oral Solution, USP 150 mg/10 mL Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity.
Precision Dose Inc. is voluntarily recalling 5 lots of Ranitidine Oral Solution, USP 150 mg/10 mL to the consumer level. Ranitidine Oral Solution, USP 150 mg/10 mL, is being recalled because of potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 19, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Class 2 medicines recall: ranitidine oral solution 30mg/ml and ranitidine 150mg tablets
Creo Pharma Limited and Tillomed Laboratories Limited are recalling all unexpired stock the products specified in the MHRA alert. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 19, 2019 Category: Drugs & Pharmacology Source Type: news
Class 2 medicines recall: ranitidine oral solution 30mg/ml and ranitidine 150mg tablets
Creo Pharma Limited and Tillomed Laboratories Limited are recalling all unexpired stock of the products specified in the MHRA alert. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 19, 2019 Category: Drugs & Pharmacology Source Type: news
Golden State Medical Supply, Inc. Issues a Voluntary Nationwide Recall of Ranitidine Hydrochloride 150mg and 300mg Capsules (Manufactured by Novitium Pharma LLC) Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA)
Golden State Medical Supply, Incorporated (GSMS, Inc) based upon a manufacturer ’s recall by Novitium Pharma LLC (Novitium), is voluntarily instituting a recall of all quantities and lots, within expiry, of Ranitidine HCl 150mg and 300mg Capsules to the consumer level because of potential presence of (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Ranitidine Tablets, USP, 150mg and 300mg, and Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL, Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity
Amneal Pharmaceuticals, LLC. Bridgewater, New Jersey is voluntarily recalling Ranitidine Tablets, 150 mg and 300 mg, and Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL to the consumer level. A listing of the recalled lots is identified below.
Ranitidine Tablets, USP, 150 mg and 300 mg (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 12, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
American Health Packaging Issues Voluntary Nationwide Recall of Ranitidine Syrup (Ranitidine Oral Solution USP) 150 mg/10 mL Liquid Unit Dose Cups Due to the Detection of N-nitrosodimethylamine (NDMA) Impurity
American Health Packaging is voluntarily recalling eight lots of Ranitidine Syrup (Ranitidine Oral Solution USP) 150 mg/10 mL Liquid Unit Dose Cups to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the f (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 8, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Strides Pharma relaunches Ranitidine tablets in US
The company had suspended sales of its generic Ranitidine tablets after the USFDA found contamination in some Ranitidine tablets sold by various companies with potentially cancer causing impurities, NDMA. Strides said now the drug meets the limits prescribed by the US drug regulator. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 7, 2019 Category: Pharmaceuticals Source Type: news
Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 38 Lots of Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL Due to the Detection of NDMA (Nitrosodimethylamine) Impurity
Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 1 lot of Ranitidine Tablets 150mg to the retail level and 37 lots of Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL to the consumer level due to the detection of NDMA (Nitrosodimethylamine) Impurity in (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 7, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA says ranitidine no more dangerous than ‘smoked meats’
Since all the hoopla surrounding ranitidine began, the FDA has been cautious in giving a final word on how dangerous the levels of NDMA in the drug could be. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 5, 2019 Category: Pharmaceuticals Source Type: news
Ranitidine recall impacts Dr Reddy's P & L by Rs 40-crore
Dr Reddy's Laboratories which initiated a voluntary recall of its Ranitidine at the retail level for over-the-counter products and at the consumer level sold in the US due to confirmed contamination with N-Nitrosodimethylamine established by FDA following the ongoing investigation which reported carcinogenic impurity in the drug at low levels. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 3, 2019 Category: Pharmaceuticals Source Type: news
